Media coverage about Proteon Therapeutics (NASDAQ:PRTO) has been trending somewhat negative this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of -0.04 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.7091080090753 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Proteon Therapeutics (PRTO) traded down $0.05 during trading hours on Thursday, hitting $1.85. The stock had a trading volume of 17,800 shares, compared to its average volume of 19,000. Proteon Therapeutics has a one year low of $1.10 and a one year high of $2.75. The firm has a market cap of $33.48, a price-to-earnings ratio of -0.83 and a beta of 1.62.
PRTO has been the topic of several recent research reports. Zacks Investment Research raised Proteon Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.50 price objective on the stock in a report on Tuesday, October 17th. HC Wainwright reissued a “hold” rating and set a $2.30 price objective on shares of Proteon Therapeutics in a report on Wednesday, November 8th. Finally, Robert W. Baird reissued a “hold” rating and set a $2.00 price objective on shares of Proteon Therapeutics in a report on Friday, November 10th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Proteon Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.20.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.